KLRS
Kalaris Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$148.12M
P/E Ratio
—
EPS
$-2.97
Beta
—
52W High
$11.88
52W Low
$2.14
50-Day MA
$8.65
200-Day MA
$6.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. The company is headquartered in Palo Alto, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-46.14M |
| Operating Margin | 0.00% |
| Return on Equity | -308.10% |
| Return on Assets | -45.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.44 |
| Price-to-Book | 1.69 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $22.93M |
| Float | $6.05M |
| % Insiders | 10.27% |
| % Institutions | 78.86% |
Analyst Ratings
Consensus ($20.33 target)
1
Strong Buy4
Buy1
HoldData last updated: 4/8/2026